• Galderma celebrates the 25^th anniversary of the approval of Sculptra^®, the first proven regenerative biostimulator, with new data, another approval, and expanding treatment applications^1-5
• New data presented at this year’s American Society for Dermatologic Surgery Annual Meeting and published in the prestigious Journal of Drugs in Dermatolo

• Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra^® across nine diverse patient profiles and journeys, over two years¹ 
• Backed by over 25 years of clinical use, Sculptra continues to prove its versatility as a regenerative treatment

• Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms¹
• Studies investigating the efficacy of Sculptra on areas beyond the face show patient

– Galderma reaffirms its dedication to continued Sculptra innovation and scientific advancement, exploring Sculptra’s regenerative properties and potential use in non-facial treatment areas –

• Updated administration protocol means Sculptra^® offers the fastest reconstitution of any injectable poly-L-lactic acid (PLLA) available in Europe
• Updated protocol allows for faster and more convenient administration of Sculptra^® with the optional addition of lidocaine to increase patient comfort
• Update i